Cure My Disease

Don't miss your cure!

 Log in / Sign up

Personalized eye injections show promise for controlling serious vision disease

NCT ID NCT05666804

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study tested if a personalized schedule for brolucizumab eye injections works as well as a standard schedule for people with a serious eye disease called PCV. The goal was to control the disease and preserve vision while potentially giving patients fewer injections. It involved 148 participants who had not received this type of treatment before.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MACULAR POLYPOIDAL CHOROIDAL VASCULOPATHY (PCV) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novartis Investigative Site

    Daegu, Dalseo Gu, 42602, South Korea

  • Novartis Investigative Site

    Bundang Gu, Gyeonggi-do, 13620, South Korea

  • Novartis Investigative Site

    Daejeon, Korea, 35015, South Korea

  • Novartis Investigative Site

    Seoul, Korea, 02447, South Korea

  • Novartis Investigative Site

    Seoul, Korea, 03080, South Korea

  • Novartis Investigative Site

    Busan, 48108, South Korea

  • Novartis Investigative Site

    Busan, 49241, South Korea

  • Novartis Investigative Site

    Busan, 613-815, South Korea

  • Novartis Investigative Site

    Daegu, 705703, South Korea

  • Novartis Investigative Site

    Gwangju, 61469, South Korea

  • Novartis Investigative Site

    Seoul, 01000, South Korea

  • Novartis Investigative Site

    Seoul, 01869, South Korea

  • Novartis Investigative Site

    Seoul, 03722, South Korea

  • Novartis Investigative Site

    Seoul, 05505, South Korea

  • Novartis Investigative Site

    Seoul, 06273, South Korea

Conditions

Explore the condition pages connected to this study.

MACULAR POLYPOIDAL CHOROIDAL VASCULOPATHY (PCV)